

Didier MUSSO, MD,

Tahiti, French Polynesia



Professional Background

Didier Musso underwent medical training in microbiology and infectious diseases in the Medicine school of Marseille. After having obtained MD and Master degree, he went to Tahiti, French Polynesia. In French Polynesia he was director of a private diagnosis laboratory, then medical council of the Ministry of Health of French Polynesia. After medical training in blood transfusion he worked in the blood bank of French Polynesia. In 2011 he was nominated by the government of French Polynesia "Director of the diagnosis laboratory" of the Louis Malarde Institute, a public health and research institute. In this institute he created by grouping previous entities the "Unit of emerging Infectious Diseases". Since 2012 he is director of the "diagnosis laboratory" and of the "Unit of emerging Infectious Diseases" of the Institut Louis Malardé. He has an accreditation to supervise research (Habilitation à Diriger des Recherches)

Research

His research interests focus on endemic French Polynesian and Pacific infectious diseases; especially arboviroses, leptospirosis, tuberculosis and lymphatic filariasis.

His research unit was leading most of the research programs conducted in French Polynesia when the Zika virus emerged in this country in late 2013, especially the description of the severe complication of Zika virus infection and the non vector-borne transmission of the virus. He is author or co-author of more than 110 publications in the field of infectious diseases, including 17 publications in the Lancet and Lancet infectious disease, and about 60 publications about Zika virus.

Publications

In press

1. Aubry M, Laughhunn A, Santa Maria F, Lanteri MC, Stassinopoulos A, **Musso D**. Amustaline (S-303) Treatment Inactivates High Levels of Chikungunya virus in Red Blood Cell Components. *Vox Sanguinis*. In press. IF: 2.192
2. Gubler DG, Vasiliakis N, **Musso D**. History and emergence of Zika virus. *The Journal of Infectious Disease*. In press. IF 6.2
3. Aubry M, Laughhunn A, Santa Maria F, Lanteri MC, Stassinopoulos A, **Musso D**. Dengue virus inactivation in RBCs by amustaline. *Transfusion*. In press. IF 3.04

2017

4. **Musso D**, Bossin H, Mallet HP, Besnard M, Broult J, Baudouin L, Levi JE, Sabino EC, Ghawche F, Lanteri MC, Baud D. Zika Virus in French Polynesia, 2013-2014: anatomy of a completed outbreak. *Lancet Infectious Disease*. [http://dx.doi.org/10.1016/S1473-3099\(17\)30446-2](http://dx.doi.org/10.1016/S1473-3099(17)30446-2). IF: 22.4
5. Aubry M, Teissier A, Huart M, Merceron S, Vanhomwegen J, Roche C, Vial AL, Teururai S, Sicard S, Paulous S, Després P, Manguerra JC, Mallet HP, **Musso D**, Deparis X, Cao-Lormeau VM. Ross River virus seroprevalence, French Polynesia, 2014-2015. *Emerging infectious diseases*. 2017; 23: 1751-3. IF 8.2
6. **Musso D**, Richard V, Teissier A, Stone M, Lanteri MC, Latoni G, Alsina J, Reik R, Busch MP for the Recipient Epidemiology and Donor Evaluation Study (REDS-III) ZIKV Study Group. Detection of ZIKV RNA in semen of asymptomatic blood donors. *Clinical Microbiology and Infection*. 2017; 23: doi: 10.1016/j.cmi.2017.07.006. IF: 5.3

7. Guernier V, Richard V, Nhan T, Rouault E, Tessier A, **Musso D**. Leptospira diversity in animals and humans in Tahiti, French Polynesia. *Plos NTD*. 2017; 11: doi: 10.1371/journal.pntd.0005676. IF: 3.948
8. **Musso D**, Lanteri ML. Zika virus in Singapore: unanswered questions. *Lancet Infectious Disease*. 2017;17:782–3. IF: 22.4
9. Santa Maria F, Laughhunn A, Lanteri M, Aubry M, **Musso D**, Stassinopoulos A. Inactivation of Zika virus in platelet components using amotosalen and ultraviolet A illumination. *Transfusion*. 2017; 57: 2016-25. IF: 3.04
10. Aubry M, Teissier Y, Mapotoake M, Teissier A, Gierd M, **Musso D**, Cao-Lormeau VM. High risk of dengue type 2 outbreak in French Polynesia, 2017. *Eurosurveillance*. 2017; 22: doi: 10.2807/1560-7917.ES.2017.22.14.30505. IF:5.9
11. Baud D, Gubler DJ, Sachaunb B, Lanteri M, **Musso D**. An update on Zika virus infection. *The Lancet*. 2017; 390: 2099-109. IF: 45.217
12. Lau C, Aubry M, **Musso D**, Teissier A, Paulous S, Després P, de-Lamballerie X, Pastorino B, Cao-Lormeau VM, Weinstein P. New evidence for endemic circulation of Ross River Virus in the Pacific Islands and potential for emergence. *International Journal of Infectious Disease*. 2017; 57: 73-6. IF: 1.89
13. **Musso D**, Lanteri MC. Emergence of Zika virus: where does it come from and where is it going to? *Lancet Infectious Disease*. 2017; 17: 255. IF: 22.4
14. Stone M, Lanteri M, Bakkour S, Deng X, Galel S, Linnen J, Munoz-Jordan J, Lanciotti R, Rios M, Gallian P, **Musso D**, Leci J, Bush M. Analytical performance of donor NAT screening diagnostic real-time PCR assays for detection of Zika virus RNA. *Transfusion*. 2017; 57 : doi: 10.1111/trf.14031. IF: 3.04
15. Aubry M, Teissier A, Huart M, Merceron S, Vanhomwegen J, Roche C, Berry AL, Teururai S, Sicard S, Paulous S, Després P, Manuguerra JC, Mallet HP, **Musso D**, Deparis X, Cao-Lormeau VM. Zika seroprevalence, French Polynesia, 2014-2015. *Emerging infectious disease*. 2017; 23: 669-72. IF: 6.75
16. Bierlaire D, Lastère S, Maugain S, Brout J, **Musso D**, Broult J. Zika virus and blood transfusion, the experience of French Polynesia. *Transfusion*. 2017; 57: 729–33. IF: 3.04
17. Phelipeau M, Asmar S, Osman DA, Sassi M, Robert C, Michelle C, **Musso D**, Drancourt M. Mycobacterium massiliopolynesiensis" sp. nov., a rapidly-growing mycobacterium of medical interest related to *Mycobacterium phlei*. *Scientific report Nature*. 2017 ; 7: doi: 10.1038/srep40443. IF : 5.228
18. Laughhunn A, Felicia SM, Brout J, Lanteri M, Stassinopoulos A, **Musso D**, Aubry. M. Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components. *Transfusion*. 2017; 57: 779–89. IF: 3.04
19. Vouga M, **Musso D**, Shaub B, Panchaud A, Baud D. Zika virus: are we going too far? *The Lancet*. 2017; 389: doi: 10.1016/S0140-6736(17)30013-2. IF: 45.217
20. Baud D, **Musso D**, Vouga M, Vulliemoz N. Zika virus: a new threat to human reproduction. *American Journal of Reproductive Immunology*. 2017; 77: doi: 10.1111/aji.12614. IF: 2.916
21. **Musso D**, Brout J, Bierlaire D, Aubry M. Prevention of transfusion-transmitted Zika virus in French Polynesia, nucleic acid testing versus pathogen inactivation. *ISBT series*. 2017; 12: 254-59. IF: 2.628
22. Gérardin P, Cao-Lormeau VM, **Musso D**, Després P, Besnard M. Zika rash and increased risk of congenital brain abnormalities. *The Lancet*. 2017; 389: 151-152. IF: 45.217
23. Blümel J, **Musso D**, Teitz S, Miyabayashi T, Boller K, Schnierle BS, Baylis SA. Inactivation and removal of Zika virus during manufacture of plasma derived medicinal products. *Transfusion*. 2017; 57: 790-6. IF: 3.04
24. Osman DA, Phelipeau M, Drancourt M, **Musso D**. Diversity of *Mycobacterium tuberculosis* lineages, French Polynesia. *Journal of Microbiology Infection and Immunity*. 2015; 50: 199-206. IF: 2.077
- 2016**
25. Parola P, **Musso D**, Raoult D. *Rickettsia felis*: the next mosquito-borne outbreak? *The Lancet Infectious Disease*. 2016; 16: 1112-3. IF: 22.4
26. **Musso D**, Lanteri M. Thoughts around the Zika virus crisis. *Current Infectious Disease reports*. 2016; 18: 46. IF: 1.493
27. Baud D, Gerardin P, Merriam A, Alves MP, **Musso D**, Genton B, Panchaud A. Harness shared data in international ZIKV registry. *British Medical Journal*. 2016; 355: doi: 10.1136/bmj.i5319. IF:19.99
28. Vouga M, Alves M P, Eperon I, Eperon G, Rochat L, Sahli R, **Musso D**, Baud D. Virus Zika: de la recherche au vaccin. *Revue Medicale Suisse*. 2016; 12 :1-4
29. Lagier JC, Kheliaffa S, Tidjani Alou M, Ndongo S, Dione N, Hugon P, Caputo A, Cadoret F, Traore S, Seck EH, Dubourg G, Durand G, Mourembou G, Guilhot E, Togo A, Bellali S, Bachar D, Cassir N, Bittar F, Delerce J, Mailhe M, Ricaboni D, Bilen M, Dangui NPM, Badiane ND, Valles C, Mouelhi D, Diop K, Million M, **Musso D**, Abraha J, Azhar E, Bibi F, Yasir M, Diallo A, Sokhna C, Djossou F, Vitton V, Robert CT, Rolain JM, La Scola B, Fournier PE, Levasseur A, Raoult D. Culture of previously uncultured members of the human gut microbiota by culturomics. *Nature microbiology*. 2016; doi: 10.1038/nmicrobiol.2016.203. IF: 24.7
30. Pettersson JH, Eldholm V, Seligman SJ, Lunkvist A, Falconar AK, Gaunt MW, **Musso D**, Nougairede A, Charrel R, Gould EA, de Lamballerie X. How did Zika virus emerge in the Pacific islands and Latin America? *mBio*. 2016; 7: doi: 10.1128/mBio.01239-16. IF: 6.786
31. **Musso D**, Brout J,Aubry M. Zika virus and blood transfusion, experiences from French Polynesia. *Vox sanguinis*. 2016; 111: 73. IF: 2.847
32. **Musso D**, Gould E, Lanteri M. Documentation of transfusion-transmitted arbovirus infections in endemic areas. *Transfusion*. 2016; 56: 3143-4. IF: 3.04

33. **Musso D**, Baud D, Fredman D. Should testing of donors be restricted to area with active Zika virus circulation? *Lancet Infectious Disease*. 2016; 16: 1108-9. IF: 22.433
34. Castellanos JE, Villamil-Gómez WE, Rodríguez-Morales AJ, Uribe-García AM, González-Arismendy E, Calvo EP, Álvarez-Mon M, **Musso D**. Zika, Dengue and Chikungunya Co-Infection in a Pregnant Woman from Colombia. *International Journal of Infectious Diseases*. 2016; 51: 135-8. IF: 1.89
35. Laroche M, Marie J, Mediannikov O, Almeras L, Berenger JM, **Musso D**, Parola P. A novel ehrlichial agent detected in tick in French Polynesia. *Ticks and Tick-borne Disease*. 2016; 7: 1203-8. IF: 2.88
36. Panchaud A, Vouga M, **Musso D**, Diaz SA, Baud D. An international registry for women exposed to zika virus during pregnancy: time for answers. *Lancet Infectious Disease*. 2016; 16: 995-6. IF: 22.433
37. Troesemeier J-H, **Musso D**, Bluemel J, Thézé J, Pybus O, Baylis S. Genome sequence of a candidate World Health Organization reference strain for Zika virus for nucleic acid testing. *Genome announcement*. 2016; 4: doi: 10.1128/genomeA.00917-16.
38. Nhan TX, Bonnieux E, Rovery C, de Pina JJ, **Musso D**. Fatal leptospirosis and chikungunya co-infection : do not forget leptospirosis during chikungunya outbreaks. *IDCases*. 2016; 5: 12-4
39. Mallet HP, Vial AL, **Musso D**. Description de l'épidémie à virus Zika survenue en Polynésie française entre octobre 2013 et mars 2014. *Bulletin épidémiologique hebdomadaire*. 2016; 20-21: 367-73.
40. **Musso D**, Teissier A, Rouault E, Teururai S, de Pina JJ, Nhan T-X. Detection of chikungunya virus in saliva and urine. *Virology Journal*. 2016; 13: doi: 10.1186/s12985-016-0556-9. IF: 2.181
41. Lanteri M, Kleinlan S, Glynn S, **Musso D**, Hoots K, Custer B, Sabino E, Bush M. 2016. Zika virus: A new threat to the safety of the blood supply with worldwide impact and implications. *Transfusion*. 2016; 56: 1907-14. IF: 3.526.
42. Vouga M, **Musso D**, Panchaud A, Baud D. Clinical management of pregnant women exposed to Zika virus. *The Lancet Infectious Diseases*. 2016; 16: doi: 10.1016/S1473-3099(16)30083-4. IF: 22.433
43. **Musso D**, Stramer SL, Bush MP. Zika virus, a new challenge for blood transfusion. *The Lancet*: 2016; 387: 1993-4. IF: 45.217
44. **Musso D**, Baud D, Gubler DJ. Zika virus, what do we know. *Clinical Microbiology and Infection*. 2016; 22:494-6. IF: 5.728
45. **Musso D**, de Pina JJ, Nhan T, Deparis X. Uncommon presentation of Zika fever or co-infection? *The Lancet*. 2016; 387: 1812-3. IF: 45.217
46. Baud D, Mieghem TV, **Musso D**, Truttmann AC, Panchaud A, Vouga M. Clinical management of pregnant women exposed to Zika virus. *Lancet Infectious Disease*. 2016; 16: doi: 10.1016/S1473-3099(16)30008-1. IF: 22.433
47. **Musso D**, Aubry M, Broutet J, Stassinopoulos A, Green J. Zika virus: new emergencies, potential for severe complications, and prevention of transfusion-transmitted Zika fever in the context of arboviruses co-circulation. *Blood transfusion*. 2017; 15: 272-273. IF: 2.372
48. Cimmino T, Metidji S, Labas N, Le Page S, **Musso D**, Raoult D. Genome sequence and description of *Actinomyces polynesiensis* str. MS2 sp. nov. isolated from the human gut. *New Microbes and New Infections*. 2016; 12: 1-5.
49. Lau C, **Musso D**, Fournier PE, Parola P, Raoult D, Weinstein P. Absence of serological evidence of *Rickettsia* spp., *Bartonella* spp., *Ehrlichia* spp. and *Coxiella burnetii* infections in American Samoa. *Tick and tick-borne diseases*. 2016; 7: 703-5. IF: 2.718
50. **Musso D**. Emergence du virus Zika: ne pas confondre détection d'anticorps lors d'études anciennes et circulation actuelle. *Virologie*. 2016; 20: 145-6. IF: 0.23
51. **Musso D**, Gubler DJ. Zika virus. *Clinical Microbiology Reviews*. 2016; 29: 487-524. IF: 17.406
52. Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, Vial AL, Decam C, Choumet V, Halstead S, Willison H, Musset L, Manuguerra JC, Despres P, Fournier E, Mallet HP, **Musso D**, Fontanet A, Neil J, Ghawché F. Guillain-Barré Syndrome outbreak associated with ZIKA virus infection in French Polynesia: a case-control study. *The Lancet*. 2016; 387: 1531-9. IF: 45.217
53. Nhan TX, Fallevoz T, De Pina JJ, Richard V, **Musso D**. Chikungunya virus uveitis during French Polynesia outbreak, 2014-2015. *Journal of clinical case report*. 2016;06: doi:10.4172/2165-7920.1000682. IF: 0.54
54. **Musso D**, Baud D. Zika virus: time to move from case reports to case control. *The Lancet Infectious diseases*. 2016; 16: 620-1. IF: 22.433
55. Vouga M, **Musso D**, Mieghem TV, Baud D. CDC guidelines for pregnant women during the Zika outbreak. *The Lancet*. 2016; 387:843-4. IF: 42.212
- 2015**
56. Aubry M, Finke J, Teissier A, Roche C, Broutet J, Paulous S, Després P, Cao-Lormeau VM, **Musso D**. Seroprevalence of arboviruses among blood donors in French Polynesia, 2011-2013. *International Journal of Infectious Diseases*. 2015; 41: 11-2. IF: 1.89
57. Metidji S, Lagier JC, Khelaifia S, Labas N, **Musso D**, Raoult D, Sankar SA, Fournier PE. Clostridium polynesiense sp. nov., a new member of the human gut microbiota in French Polynesia. *Anaerobe*. 2015; 36: -87. IF: 2.479
58. Nhan T, **Musso D**. Emergence du Zika virus. *Virologie*. 2015;19:225-235. IF: 0.23
59. **Musso D**, Nhan T. Emergence of Zika virus. *Clinical Microbiology*. 2015;4: doi:10.4172/2327-5073.1000222. IF: 0,7
60. Phelipeau M, Osman DA, **Musso D**, Drancourt M. Epidemiology of nontuberculous mycobacteria in French Polynesia. *Journal of Clinical Microbiology*. 2015; 53: 3798-804. IF: 4.153

61. **Musso D.** Zika virus: from French Polynesia to Brazil. Emerging Infectious Disease. 2015;21:1887. IF: 7.327
62. Aubry M, Richard V, Green J, Broult J, **Musso D.** Amotosalen and Ultraviolet A light inactivate Zika virus in plasma. Vox Sanguinis. 2015; 109: 309. IF: 2.847
63. Aubry M, Richard V, Broult J, Green J, **Musso D.** Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination. Transfusion. 2015; 56: 33-40. IF: 3.526
64. Aubry M, Finke J, Teissier A, Roche C, Broult J, Paulous S, Despres P, Cao-Lormeau VM, **Musso D.** Silent circulation of RRV in French Polynesia. International Journal of Infectious Disease. 2015; 37: 19-24. IF: 2.357
65. **Musso D**, Cao-Lormeau VM, Gubler DJ. Zika virus: following the path of dengue and chikungunya? The Lancet. 2015; 386: 243-4. IF: 45.212
66. Aboubaker Osman D, Phelipeau M, **Musso D**, Robert C, Michelle C, Croce O, Drancourt M. Draft Genome Sequence of Mycobacterium tuberculosis strain MT11, which represents of a new lineage. Genome announcement. 2015; 3; doi: 10.1128/genomeA.00573-15.
67. Aboubaker Osman D, Phelipeau M, **Musso D**, Robert C, Michele C, Croce O, Drancourt M. Draft Genome Sequence Mycobacterium tuberculosis strain MT43, a representative of the Manu2 genotype. Genome announcement. 2015; 3; doi: 10.1128/genomeA.00579-15.
68. **Musso D**, Roche C, Nhan T, Robin E, Teissier A, Cao-Lormeau VM. Detection of Zika virus in saliva. Journal of Clinical Virology. 2015; 68: 53-5. IF: 3.466
69. Nhan T, **Musso D.** The burden of chikungunya in the Pacific. Clinical Microbiology and Infection. 2015; 21: e47-8. IF: 5.197
70. Daures MD, Champagnat JC, Pfannstiel AP, Ringuenoire FR, Grangeon JP, **Musso D.** Filarisis serosurvey, New Caledonia, South Pacific, 2013. Parasites and vectors. 2015; 8: doi: 10.1186/s13071-015-0713-9. IF: 3.25
71. Phelipeau M, **Musso D**, Drancourt M. *Mycobacterium abscessus* pneumonia in a South Pacific islander. Journal of Microbiology Infection and Immunity. 2015;doi:10.1016/j.jmii.2015.01.008. IF: 2.077
72. Aubry M, Teissier A, Roche C, Richard V, Shan Yan A, Zizou K, Rouault E, Maria V, Lastère S, Cao-Lormeau VM, **Musso D.** Chikungunya outbreak, French Polynesia, October 2014. Emerging Infectious Disease. 2015; 21: 724-6. IF: 7.327
73. Bierlaire D, Beau F, Lastère S, **Musso D**, Broult J. Virus Zika en Polynésie Française : hemovigilance receveur. Transfusion clinique et biologique. 2014; 21: 234. IF: 0.712
74. **Musso D**, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual transmission of Zika virus. Emerging infectious diseases. 2015; 21: 359-361. IF: 7.327
75. Dernie B, Lau C, Nilles A, **Musso D**, Weinstein P. Distribution of Rickettsiosis in Oceania: past patterns and implications for the future. Acta tropica. 2015; 143: 121-33. IF: 2.519
- 2014
76. Cao-Lormeau VM, **Musso D.** Emerging arboviruses in the Pacific. The Lancet. 2014 ; 384: 1571-2. IF: 39.207
77. Nhan T, Cao-Lormeau VM, **Musso D.** Les infections à virus Zika. 2014. Revue Francophone des laboratoires. 2014; 467: 35-42
78. Dubourg G, Lagier JC, Robert C, Armougom F, Hugon P, Metidji S, Dione N, Nicole Dangui PM, Pfleiderer A, Abrahao J, **Musso D**, Papazian L, Brouqui P, Bibi F, Yasir M, Vialettes B, Raoult D. Culturomics and pyrosequencing evidence of the reduction in gut microbiota diversity in patients with broad-spectrum antibiotics. International Journal of Antimicrobial Agent. 2014; 44: 117-24. IF: 3.869
79. Nhan T, Claverie A, Roche C, Teissier A, Colleuil M, Baudet J-M, Cao-Lormeau VM, **Musso D.** Chikungunya virus imported into French Polynesia, 2014. Emerging infectious diseases. 2014; 20: 1773-4. IF: 7.327
80. **Musso D**, Richard V, Broult J, Cao-Lormeau VM. Amotosalen and ultraviolet A illumination of dengue virus in plasma. Vox Sanguinis. 2014; 107: 218. IF: 2.847
81. **Musso D**, Nilles E, Cao-Lormeau VM. Rapid spread of emerging Zika virus in the Pacific area. Clinical Microbiology and Infection. 2014; 20: 0595-6. IF: 4.578.
82. Nhan TX, Teissier, Roche C, **Musso D.** Sensitivity of real-Time PCR performed on dried sera spotted on filter paper for diagnosis of leptospirosis. Journal of Clinical Microbiology. 2014. 2014; 52: 3075-7. IF: 4.153
83. **Musso D**, Broult J, Parola P, Raoult D, Fournier PE. Absence of antibodies to *Rickettsia* spp, *Bartonella* spp, *Ehrlichia* spp. and *Coxiella burnetii* in Tahiti, French Polynesia. BMC Infectious deseases. 2014; 14: doi: 10.1186/1471-2334-14-255. IF: 3.12
84. **Musso D**, Nhan T, Robin E, Bierlaire D, Zisou K, Shan Yan A, Cao-Lormeau V-M, Broult J. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. Eurosurveillance. 2014 ;19: pii : 20761. IF: 5.491
85. **Musso D**, Richard V, Broult J, Cao-Lormeau VM. Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination. Transfusion. 2014; 54: 2924-30. IF: 3.526
86. Besnard M, Lastère S, Teissier A, Cao-Lormeau VM, **Musso D.** Evidence of perinatal transmission of Zika virus, French Polynesia, december 2013 and February 2014. Eurosurveillance. 2014; 19: pii: 20751. IF: 5.491
87. Cao-Lormeau VM, Roche C, **Musso D**, Mallet HP, Dalipanda T, Dofai A, Nogareda F, Nilles EJ, Aaskov J. Dengue virus type 3, South Pacific Islands, 2013. Emerging infectious diseases. 2014; 20: 1034-6. IF: 7.327

88. **Musso D**, Claudine Roche, Maria Marfel, Martin Bel, Eric J Nilles, VM Cao-Lormeau. Improvement of leptospirosis surveillance in remote Pacific islands using serum spotted on filter paper. International Journal of Infectious Disease. 2014; 20: 74-6. IF: 2.357
89. Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry AL, Mallet HP, Sall AA, **Musso D**. Zika virus, French Polynesia, South Pacific, 2013. Emerging infectious diseases. 2014; 20:1085-6. IF: 7.327
90. Oehler E, Watrin L, Leparc-Goffart I, Lastère S, Valour F, Baudouin L; Mallet HP, **Musso D**, Ghawche F. Zika virus infection complicated by Guillain-Barré syndrome-case report, French Polynesia, December 2013. Eurosurveillance. 2014; 19: pii: 20720. IF: 5.993
- 2013**
91. Nogareda F, Joshua C, Sio A, Shortus M, Dalipanda T, Durski K, Musto J, Puiahi E, Dofai A, Aaskov J, Cao-Lormeau V-M, **Musso D**, Dutta N, Fleisch J, Nilles E. Ongoing outbreak of dengue serotype-3 in Solomon Islands, January to May 2013. *Western Pacific Surveillance and Response Journal*, 2013; 4: doi: 10.5365/wpsar.2013.4.2.013.
92. Hugon P, Lagier J-C, Robert C, Lepolard C, Papazian L, **Musso D**, Vialettes B and Raoult D. Molecular studies neglect apparently Gram-negative populations in the human gut microbiota. Journal of clinical microbiology. 2013; 51: 3286-93. IF: 4.153
93. **Musso D**, Lascola B. Laboratory diagnosis of leptospirosis: a challenge. Journal of Microbiology, Immunology and Infection. 2013; 46: 245-2. IF: 1.631
94. **Musso D**. Relevance of the eosinophil blood count in Bancroftian filariasis as a screening tool for treatment. Pathogen and Global Health. 2013; 107: 96-102. IF: 1.429
- 2012**
95. **Musso D**, V Vialette. Predictive value of the eosinophil count in the biological diagnosis of lymphatic filariasis in French Polynesia. Médecine et Maladies Infectieuses. 2012; 42: 585-90. IF: 0.753
96. Aubry M; Roche C, Dupont-Rouzeyrol M, Aaskov J, Viallon J, Marfel M, Lalita P, Elbourne-Duituturaga S, Chanteau S, **Musso D**, Pavlin B, Harrison D, Kool J, Cao-Lormeau VM. Use of serum and blood samples on filter paper to improve the surveillance of dengue in Pacific Island Countries. Journal of Clinical Virology. 2012; 55: 23-39. IF: 4.023
97. **Musso D**, Lascola B. Diagnostic biologique de la leptospirose. Revue francophone des laboratoires. 2012; 449: 39-49.
98. **Musso D**, Cao-Lormeau VM. Diagnostic biologique de la dengue. Revue francophone des laboratoires. 2012; 447: 53-62.
- 2011**
99. Cao-Lormeau VM, Roche C, Aubry M, Teissier A, Lastère S, Daudens E, Mallet HP, **Musso D**, Aaskov J. Recent emergence of Dengue virus serotype 4 in French Polynesia results from multiple introductions from other south Pacific islands. PLoS ONE. 2011; 6: doi: 10.1371/journal.pone.0029555. IF: 4.752
- 1997**
100. Lascola B, Fournier PE, **Musso D**, Tissot-Dupont H. Pseudo-outbreak of listeriosis elucidated by pulsed field gel electrophoresis. The European Journal of Clinical Microbiology and Infectious Diseases. 1997; 16: 756-60. IF: 3.024
101. **Musso D**, Raoult D. Serological cross reaction between *Coxiella burnetii* and *Legionella micdadei*. Clinical and Diagnostic Laboratory Immunology. 1997; 4: 208-12. IF: 2,598
102. Lascola B, **Musso D**, Carta A, Piquet P, Casalta J-P. Aortoabdominal aneurysm infected by *Yersinia enterocolitica* serotype O:9. Journal of Infection. 1997; 35: 314-5. IF: 4.073
- 1996**
103. **Musso D**, Drancourt M, Ossini S, Raoult D. Sequence of quinolone resistance-determining region of *gyrA* gene for clinical isolates and for an in vitro selected quinolone resistant strain of *Coxiella burnetii*. Antimicrobial Agents and Chemotherapy. 1996; 40: 870-3. IF: 4.565
104. **Musso D**, Raoult D. Survie Intracellulaire des micro-organismes. Revue du Praticien. 1996; 46: 2160-3.
105. Lascola B, **Musso D**, Raoult D. Infections humaines dues aux bactéries du genre *Bartonella*. Revue francophone des Laboratoires. 1997;291: 153-159.
106. **Musso D**, Di Constanzo B. Une mycobactérie peut en cacher une autre. Médecine et Maladies Infectieuses. 1996; 27: 741-2. IF: 0.753
- 1995**
107. **Musso D**, Raoult D. *Coxiella burnetii* blood culture in acute and chronic Q fever patients. Journal of Clinical Microbiology. 1995 ;33: 3129-32. IF: 4.153
108. **Musso D**, Drancourt M, Raoult D. Lack of bactericidal effects of antibiotic except aminoglycoside on *Bartonella (Rochalimaea) henselae*. Journal of Antimicrobial Chemotherapy. 1995; 36:101-8. IF: 5.338
- 1994**
109. **Musso D**, Drancourt M, Bardot J, Legre. Human infection due to the CDC group IVc-2 bacterium: case report and review. Clinical Infectious Diseases, 1994; 18:482-4. IF: 9.374
110. **Musso D**, Drancourt M, Bardot J, Legre. Human infection due to the CDC group IVc-2 bacterium: case report and review. Clinical Infectious Diseases, 1994; 18:482-4. IF: 9.374
- 1992**
111. Maurin M, **Musso D**, Charrel R, Perez R, N'Guyen A, Du-mond H, De Micco P. Résistance aux antibiotiques des bactéries hospitalières (bacilles à Gram négatif aérobies), situation en 1992 à Marseille. Médecine et Maladies Infectieuses. 1995; 25: 1-7. IF: 0.753
- 1988**
112. Jacomo V, **Musso D**, Gevaudan M-J, Drancourt M. Isolation of blood-borne *Mycobacterium avium* using the nonradioactive BACTEC 9000 MB system and comparison with a solid-culture system. Journal of Clinical Microbiology. 1998; 36: 3703-6. IF: 4.153

Publications classes par impact factor et par rang d'auteur (Publications by impact factor and rank of author)

Impact Factor	Premier auteur First author	Autre position Other position	Dernier auteur Last author	Total
> 30	4	4	1	9
20 - 30	5	5	0	10
10 - 20	1	2	0	3
5 - 10	7	6	6	19
2 - 5	15	16	8	39
< 2	12	13	7	32
Total	44	46	21	112

